Forest Expects Benicar Sales To Increase With 80 Additional Sankyo Reps

Forest expects sales for the antihypertensive Benicar (olmesartan) to increase due to an additional 80 reps from its co-promotion partner Sankyo

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet